CC BY 4.0 · Rev Bras Ginecol Obstet 2019; 41(05): 277-279
DOI: 10.1055/s-0039-1688959
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Preeclampsia: New Concepts and Approach of a National Protocol

1   Departament of Gynecology and Obstetrics, Faculdade de Medicina, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
Henri Augusto Korkes
2   Departament of Obstetrics, Pontifícia Universidade Católica de São Paulo, São Paulo, SP, Brasil
› Institutsangaben
Weitere Informationen


10. Juni 2019 (online)

Importance of the Topic and Development of a National Protocol

Hypertensive syndromes, along with hemorrhagic syndromes, account for a large share of maternal deaths worldwide. In developing countries such as Brazil, maternal deaths are mostly related to hypertensive complications, and preeclampsia (PE) plays a prominent role in this scenario.[1] [2] Several factors contribute to these outcomes, such as late diagnosis, low rates of prescription of pharmacological preventive methods, inadequate prenatal care both in number and quality of visits, low and inadequate use of magnesium sulfate in the prevention of eclampsia, and poor postpartum follow-up. These factors, individually or together, can exert negative influence and increase maternal morbidity and mortality rates in our country.

The difficulty in understanding PE in terms of its etiology, pathogenesis and clinical presentation is already known. However, this aspect is aggravated because each country, region and even city services denominate and classify hypertensive syndromes in ways that generate confusion among colleagues, which delays the diagnoses and conducts. With the purpose of combating these known and undesirable difficulties, unifying the care provided to pregnant women, and reducing maternal death rates in our country, it was essential to create a national protocol on preeclampsia.

  • References

  • 1 von Dadelszen P, Payne B, Li J. , et al; PIERS Study Group. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011; 377 (9761): 219-227 . Doi: 10.1016/S0140-6736(10)61351-7
  • 2 Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33 (03) 130-137 . Doi: 10.1053/j.semperi.2009.02.010
  • 3 American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. Washington, DC: ACOG; 2013 . Accessed: March 20, 2018.
  • 4 ACOG Practice Bulletin No. 202 Summary: gestational hypertension and preeclampsia. Obstet Gynecol 2019; 133 (01) 211-214 . Doi: 10.1097/AOG.0000000000003019
  • 5 Brown MA, Magee LA, Kenny LC. , et al; International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018; 72 (01) 24-43 . Doi: 10.1161/HYPERTENSIONAHA.117.10803
  • 6 World Health Organization. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. 2011 . Accessed: June 13, 2018.
  • 7 Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2014; (06) CD001059 . Doi: 10.1002/14651858.CD001059.pub4
  • 8 von Dadelszen P. M11.1 Identifying risk in women with pre-eclampsia: the validated PIERS model. Pregnancy Hypertens 2010; 1: S8 . Doi: 10.1016/S2210-7789(10)60045-1